JON81497

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555775

CAS#: 165381-49-7

Description: JON81497 is a propylamino U amidite, which is belong to modified Amidite or Nucleoside phosphoramidite. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).


Chemical Structure

img
JON81497
CAS# 165381-49-7

Theoretical Analysis

MedKoo Cat#: 555775
Name: JON81497
CAS#: 165381-49-7
Chemical Formula: C44H53F3N5O10P
Exact Mass: 899.3482
Molecular Weight: 899.902
Elemental Analysis: C, 58.73; H, 5.94; F, 6.33; N, 7.78; O, 17.78; P, 3.44

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Propylamino ​uridine amidite, propylamino U amidite; 2'-O-Trifluoroacetamido propyl Uridine CED phosphoramidite; JON81497; JON-81497; JON 81497;

IUPAC/Chemical Name: (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-(3-(2,2,2-trifluoroacetamido)propoxy)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite

InChi Key: JDBCEYQBKYYZNE-OVLVZACUSA-N

InChi Code: InChI=1S/C44H53F3N5O10P/c1-29(2)52(30(3)4)63(60-27-10-23-48)62-38-36(61-40(51-25-22-37(53)50-42(51)55)39(38)58-26-11-24-49-41(54)44(45,46)47)28-59-43(31-12-8-7-9-13-31,32-14-18-34(56-5)19-15-32)33-16-20-35(57-6)21-17-33/h7-9,12-22,25,29-30,36,38-40H,10-11,24,26-28H2,1-6H3,(H,49,54)(H,50,53,55)/t36-,38-,39-,40-,63?/m1/s1

SMILES Code: O=C(NC(C=C1)=O)N1[C@H](O2)[C@H](OCCCNC(C(F)(F)F)=O)[C@H](OP(N(C(C)C)C(C)C)OCCC#N)[C@H]2COC(C3=CC=C(OC)C=C3)(C4=CC=CC=C4)C5=CC=C(OC)C=C5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 899.902 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Salinas JC, Seth PP, Hanessian S. Design And Synthesis Of An Azabicyclic Nucleoside Phosphoramidite For Oligonucleotide Antisense Constructs. Nucleosides Nucleotides Nucleic Acids. 2020;39(1-3):384-406. doi: 10.1080/15257770.2019.1646916. Epub 2019 Aug 5. PMID: 31380707.

2: Sato K, Matsuda A. Synthesis of 2-Amino-4-Fluoropyridine-C-Nucleoside Phosphoramidite for Incorporation into Oligonucleotides. Curr Protoc Nucleic Acid Chem. 2019 Jun;77(1):e77. doi: 10.1002/cpnc.77. Epub 2019 Feb 12. PMID: 30747492.

3: Kolganova NA, Florentiev VL, Chudinov AV, Zasedatelev AS, Timofeev EN. Simple and stereoselective preparation of an 4-(aminomethyl)-1,2,3-triazolyl nucleoside phosphoramidite. Chem Biodivers. 2011 Apr;8(4):568-76. doi: 10.1002/cbdv.201000047. PMID: 21480503.

4: Kataoka M, Hayakawa Y. Catalytic use of 1 H-tetrazole in condensation nucleoside and a nucleoside phosphoramidite. Nucleic Acids Symp Ser. 1995;(34):175-6. PMID: 8841609.

5: Gryaznov SM, Letsinger RL. Selective O-phosphitilation with nucleoside phosphoramidite reagents. Nucleic Acids Res. 1992 Apr 25;20(8):1879-82. doi: 10.1093/nar/20.8.1879. PMID: 1579488; PMCID: PMC312301.

6: Roget A, Bazin H, Teoule R. Synthesis and use of labelled nucleoside phosphoramidite building blocks bearing a reporter group: biotinyl, dinitrophenyl, pyrenyl and dansyl. Nucleic Acids Res. 1989 Oct 11;17(19):7643-51. doi: 10.1093/nar/17.19.7643. PMID: 2798121; PMCID: PMC334873.

7: Pon RT, Damha MJ, Ogilvie KK. Modification of guanine bases by nucleoside phosphoramidite reagents during the solid phase synthesis of oligonucleotides. Nucleic Acids Res. 1985 Sep 25;13(18):6447-65. doi: 10.1093/nar/13.18.6447. PMID: 4059050; PMCID: PMC321970.



Additional Information

5'-​O-​(4,​4'-​Dimethoxytrityl)​-​2'-​O-​trifluoroacetamidopr​opyl-​uridine-​3'-​(2-​cyanoethyl diisopropylphosphora​midite)
Nucleoside phosphoramidites were first introduced in 1981 by Beaucage and Caruthers. To avoid undesired side reactions, reactive hydroxy and exocyclic amino groups present in natural or synthetic nucleosides are appropriately protected. As long as a nucleoside analog contains at least one hydroxy group, the use of the appropriate protecting strategy allows one to convert that to the respective phosphoramidite and to incorporate the latter into synthetic nucleic acids. To be incorporated in the middle of an oligonucleotide chain using phosphoramidite strategy, the nucleoside analog must possess two hydroxy groups or, less often, a hydroxy group and another nucleophilic group (amino or mercapto). Examples include, but are not limited to, alternative nucleotides, LNA, morpholino, nucleosides modified at the 2'-position (OMe, protected NH2, F), nucleosides containing non-canonical bases (hypoxanthine and xanthine contained in natural nucleosides inosine and xanthosine, respectively, tricyclic bases such as G-clamp, etc.) or bases derivatized with a fluorescent group or a linker arm. (https://en.wikipedia.org/wiki/Nucleoside_phosphoramidite). Structurally modified nucleic acid analogs have been introduced to developed probes that act as potent & selected nucleic acid based therapeutics & diagnostics. In addition to this, these probes have also showed potential application molecular biology3 & Nanotechnology research and development. Incorporation of modified purines and pyrimidines has been utilized to optimize DNA-protein interactions and sequence recognition for many pro­teins and enzymes such as repressor proteins, restriction endonucleases, modification enzymes, and promoters. Applications for a variety of key modifications are described on the following pages. ChemGenes carries a wide variety of modified DNA phosphoramidites and supports and all these modifications are described under these section.